DXCM · XBRL financial data

Dexcom financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (DXCM's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	1,927	2,449	2,910	3,622	4,033	4,662
Cost of goods and services sold	647	768	1,027	1,333	1,595	1,860
Gross profit	1,280	1,681	1,883	2,289	2,438	2,802
Research and development	360	517	484	506	552	599
Selling, general and administrative	621	811	1,000	1,185	1,286	1,291
Total operating expenses	981	1,415	1,492	1,691	1,838	1,890
Other operating income (expense)	—	—	—	(4)	(5)	4
Operating income (loss)	300	266	391	598	600	912
Interest expense	85	100	19	20	19	18
Other income (expense)	16	(2)	18	113	109	177
Income tax expense (benefit)	(269)	19	50	169	133	252
Net income (loss)	494	155	341	542	576	836
Earnings per share, basic‡ USD per share	0.02	0.01	0.88	1.40	1.46	2.14
Earnings per share, diluted‡ USD per share	0.02	0.01	0.82	1.30	1.42	2.09
Weighted average shares, basic‡ millions of shares	24,166	24,755	389	386	394	390
Weighted average shares, diluted‡ millions of shares	24,960	25,626	428	426	413	406

‡ Per-share figures and share counts are adjusted for the 4-for-1 stock split (December 2021); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 4-for-1 stock split (June 2022); filings made before it reported them unadjusted.
† Share count changed about 1/64 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (DXCM's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	818	1,053	642	566	606	918
Marketable securities	—	1,360	1,810	2,160	1,730	—
Marketable securities, non-current	—	321	—	—	248	—
Accounts receivable	429	514	713	974	1,006	1,216
Inventory	235	357	307	560	543	629
Prepaid and other current assets	54	82	193	168	174	189
Total current assets	3,425	3,684	3,669	4,426	4,301	4,033
Property and equipment, net	515	802	1,056	—	—	—
Right-of-use asset	93	88	80	71	63	77
Goodwill	19	27	26	25	23	24
Total assets	4,291	4,864	5,392	6,265	6,485	6,340
Total current liabilities	614	721	1,839	1,556	2,932	2,143
Lease liability, non-current	102	99	95	80	65	73
Total liabilities	2,464	2,612	3,260	4,196	4,382	3,594
Retained earnings (accumulated deficit)	(202)	(47)	480	1,021	1,598	2,434
Total stockholders' equity	1,552	2,252	2,132	2,069	2,103	2,746
Total liabilities and equity	4,291	4,864	5,392	6,265	6,485	6,340
Common shares outstanding (cover page)‡ millions of shares	24,621	24,849	386	386	391	385

‡ Per-share figures and share counts are adjusted for the 4-for-1 stock split (December 2021); filings made before it reported them unadjusted.
‡ Per-share figures and share counts are adjusted for the 4-for-1 stock split (June 2022); filings made before it reported them unadjusted.
† Share count changed about 1/64 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (DXCM's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	494	155	341	542	576	836
Stock-based compensation	119	113	127	151	170	160
Depreciation and amortization	67	102	156	186	218	252
Net cash from operating activities	476	443	670	749	990	1,441
Purchases of property and equipment	199	389	365	237	359	364
Net cash from investing activities	(1,018)	(216)	(522)	(507)	(208)	536
Proceeds from issuing common stock	15	20	23	27	28	28
Share repurchases	0	0	558	689	750	500
Net cash from financing activities	912	10	(553)	(319)	(735)	(1,686)
Net change in cash	372	235	(410)	(76)	40	312

† Share count changed about 1/64 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Dexcom	961	1,345	326*	373.0M	—	Q3 FY26 10-QSep 30, 2026
GE HealthCare Technologies	2,826	5,513	907*	452.1M	—	Q3 FY26 10-QSep 30, 2026
Resmed	1,011	1,415	422	140.7M	—	Q1 FY27 10-QSep 30, 2026
Edwards Lifesciences	2,907	1,741	652*	576.4M	—	Q2 FY26 10-QJun 30, 2026
STERIS	482	1,493	367	97.5M	—	Q1 FY27 10-QJun 30, 2026
Insulet	535	802	88*	69.4M	—	Q2 FY26 10-QJun 30, 2026
MiniMed Group	207	843	(49)	281.3M	2.3 quarters	Q1 FY27 10-QJul 31, 2026
Zimmer Biomet Holdings	410	2,177	448*	190.7M	—	Q2 FY26 10-QJun 30, 2026
Becton Dickinson	708	4,983	not reported	272.4M	—	Q3 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.